Background {#Sec1}
==========

Hodgkin Lymphoma (HL) has well established treatment regimens that have yielded highly effective, long-term cure rates \[[@CR1], [@CR2]\]. In 2015, there were an estimated 9050 new cases of the disease, which is a much lower incidence than more commonly occurring cancers. The number of persons living with HL in 2012, however, was estimated to approach 190,000 \[[@CR3]\]. Thus, from an oncologic perspective the successful treatment for HL over the last 25 years has led to a high number of long-term survivors.

The incidence of HL is bimodal by age with the first peak within adolescence and young adulthood, ages 15--40, and the second after age 55 \[[@CR4]\]. For younger people with HL, the aggressive cancer treatment often interrupts important developmental milestones, such as graduation from high school or college, establishing relationships, finding a first apartment or getting a job. Despite the decades of curative therapy for HL, comparatively little is known about how HL affects health-related quality of life (HRQL)---through diagnosis and treatment. Therefore, healthcare providers lack the information that they need regarding how best to intervene in a timely and effective manner to mediate HL's acute and late-term effects.

HRQL is a multidimensional construct, which reflects the World Health Organization's definition of health as incorporating physical, mental, and social health \[[@CR5]\]. The history of HRQL assessment largely parallels the advances in HL therapy with most of the instrument development and large-scale validation studies for adults commencing in the 1980's. The first randomized controlled trial (RCT) containing an HRQL outcome was reported in 1986 by Croog and Levine \[[@CR6]\]. In contrast, instrument development for children lagged considerably, but psychometrically robust measures are now available for most patients across the age continuum. Several validated instruments address the multidimensional construct, while others focus on individual dimensions or domains of HRQL, such as physical or psychosocial functioning. Still others measure individual symptoms, such as pain, nausea or fatigue. The selection of a particular instrument or instruments is informed by the particular study question.

Although treatment regimens are well-established, the impact on HL patient's HRQL from diagnosis through long-term survivorship is still unclear. In this study, we report on a systematic review that we conducted on the HRQL literature to answer the following research question: What is the HRQL impact of HL and its treatment as reflected in the current literature? Our goals were to: (1) describe the available literature on HRQL in HL, (2) assess the quality of these studies and, (3) identify gaps in the available literature and recommend further areas of research.

Methods {#Sec2}
=======

Literature search strategy {#Sec3}
--------------------------

Our review was guided by the PRISMA statement \[[@CR7]\]. We searched Medline, CINAHL and PsychInfo using Medical Subject Headings and keywords, such as *Hodgkin disease, quality of life, health- related quality of life, well-being, functional status, health status* and *experiential health status* for articles published since inception to end of May 2016 that reported primary HRQL data specific to HL patients. A priori, we sought studies that assessed single or multi-dimensional HRQL domains or discrete symptoms, such as fatigue. Study design was not part of the inclusion/exclusion criteria as our goal was to examine the entirety of the HRQL in HL literature. Studies were excluded if they (1) did not report primary HRQL separately for HL patients or (2) were not available in English. Following this database search, a citation analysis was performed on review articles to identify additional articles (see Fig. [1](#Fig1){ref-type="fig"}). This was done to ensure that this review afforded the most comprehensive representation of the literature. Selected articles included HL patients across the age (children and adults) and care continuum, from initial diagnosis through long-term survivorship.Fig. 1Systematic review flow diagram following PRISMA guidelines

Review of the abstracts and full-text articles {#Sec4}
----------------------------------------------

The six-member team initially reviewed a training set of 50 abstracts for consideration in the study, applying established inclusion/exclusion criteria to ensure consistency across all team members. Subsequently, teams of two reviewers independently applied inclusion/exclusion criteria to the remaining abstracts and then full text articles, resolving any discrepancies through consensus. Full text articles meeting inclusion criteria were independently data extracted using a standardized data extraction form and checked for accuracy by a second review.

Review articles were handled differently from original reports. Because the review articles did not include original data, we did not perform data extraction on review articles. The review articles provided background information and were used in the citation analysis.

Quality indicators {#Sec5}
------------------

The methodological quality of each study was evaluated by a set of six predetermined criteria, adapted from previously published systematic reviews \[[@CR8], [@CR9]\]. Quality assessment (QA) criteria included: (1) description of ≥2 demographic variables specific to HL patients, such as age and gender; (2) ≥2 clinical characteristics, specific to HL patients, such as stage or site of disease; (3) sample size ≥50 HL participants; (4) HL-specific HRQL scores; presented as a mean summary score and measure of variability in either table or text format; (5) analysis of HRQL scores by HL specific demographic characteristics and (6) HL results compared within groups. The final QA checklist scores were summed by each article to give an overall quality score, ranging from 0 to 6 in which higher scores indicated higher quality.

Results {#Sec6}
=======

The database search totaled 792 unique records. Following the screening process, 80 studies, published between 1986 and 2015, were identified, including 65 primary studies and 15 review articles. Reasons for rejection of full text articles included HL data not separated out, no HRQL data reported, not available in English, or an editorial article. The following section reports on the 65 primary studies.

Study characteristics {#Sec7}
---------------------

Study characteristics are presented in Table [1](#Tab1){ref-type="table"}. Of the 65 studies, 53 (82 %) utilized cross-sectional design; only 12 (18 %) used longitudinal design. Of the 12 longitudinal studies, seven included individuals who were off treatment, while five included samples who were both on and off treatment. We identified three longitudinal RCTs \[[@CR10]--[@CR12]\], of which patients were followed from the time of diagnosis through up to 10 years of survivorship. These studies accrued large samples and made comparison of HRQL according to randomized treatment groups. The 53 cross sectional studies reported on 35 unique cohorts and only one included patients both on and off treatment. The remaining 52 (98 %) cross-sectional studies only included individuals who were off active treatment.Table 1Study characteristics (*N* = 65)Study design, *n* (%) Comparator: RCT3 (5) Comparator: cohort14 (22) Cohort45 (69) Comparator: case control3 (5)Study type, *n* (%) Longitudinal12 (18) Cross-sectional53 (82)Study setting, *n* (%) In person18 (28) Remote42 (65) NS5 (8)Decade of publication Before 19956 (9) 1995 to 200425 (38) 2005 to June 201534 (52)Study sponsor, *n* (%) Cooperative group7 (11) Investigator initiated58 (89)Geographic location, *n* (%) USA19 (29) Norway17 (26) Netherlands7 (11) Germany4 (6) Other Europe10 (15) South America4 (6) Canada3 (5) Asia1 (2)*n* (HL patients) Median (range)132 (12--3208) 25--75^th^ percentile58--280Treatment status, *n* (%) Active and off treatment6 (9) Off treatment only59 (91)Age^a^ Mean (*n* = 33)39.6 Median (*n* = 21)38Gender, % Female (*n* = 54)44.0 % Range0--100 %^a^Age: 3 studies with multiple arms, 6 studies NS*RCT* randomized controlled trial, *NS* not stated

The sample size of HL patients varied considerably with 78 % of studies including a sample of 50 or more HL patients. For the 53 cross-sectional studies, the median sample size was 135 (range 15--1843) and for the 12 longitudinal studies the median sample size was 51 (range 12--3208). The majority of study designs were cohort (*n* = 45) and 14 used a comparator cohort design. The most common comparators were the general population (*n* = 23), other cancer patients (*n* = 12) and siblings (*n* = 3). When comparing among other cancer patients, the most common comparator included other types of lymphoma (*n* = 7). The majority of studies relied on remote data collection (*n* = 42), when specified either by mail (*n* = 35) or telephone (*n* = 6), with the remainder conducted in person. The study funding was primarily investigator initiated (*n* = 58) or via a cooperative group (*n* = 7). We did not identify any industry-funded studies. Half (52 %) of the identified studies were published after 2005. Table [2](#Tab2){ref-type="table"} contains the data extraction results.Table 2Studies assessing HRQL in Hodgkin lymphoma patients (*N* = 65)Primary AuthorYearDesignStudy TypeTimepoints (as reported)N (HL Specific)Age (HL specific)Tx StatusMeasuresDomains AssessedQuality ScoreFobair P \[[@CR26]\]1986CohortCross-sectionalMedian 9 years post treatment40336.3 meanOffCES-D, Study-specific questionnaireDomain, Symptom6Kornblith AB \[[@CR22]\]1990CohortCross-sectional6.3 years mean post treatment27337 meanOffPAIS-SR, BSI, POMS, IES, Global Sexual Satisfaction IndexDomain5Chao NJ \[[@CR37]\]1992CohortLongitudinal\<1 year post treatment24N/SOffStudy-specific questionnaireMultiD2Kornblith AB \[[@CR23]\]1992CohortCross-sectionalMean 6.3 years post treatment27337 meanOffPAIS-SR, BSI, POMS, Global Sexual Satisfaction IndexDomain6Kornblith \[[@CR48]\] AB1992CohortCross-sectionalMean 2.2 years post treatment9335 medianOffPAIS-SR, BSI, POMS, IESDomain4Bloom JR \[[@CR49]\]1993Comparator: CohortCross-sectional1 or more years post treatment8532.3 meanOffPOMS, CES-D, Social Activity ScaleDomain6van Tulder MW \[[@CR30]\]1994Comparator: CohortCross-sectionalMean 14 years since diagnosis8143.6 meanOffSF-36, Maudsley Martital QuestionnaireMultiD, Other6Joly F \[[@CR38]\]1996Comparator: Case ControlCross-sectionalMean 10 years since diagnosis9342 meanOffEORTC QLQ-C30, Study-specific questionnaireMultiD, Other6Norum J \[[@CR50]\]1996CohortCross-sectionalMedian 48 months since diagnosis4238 medianOffIES, VASDomain, Other4Norum J \[[@CR51]\]1996CohortCross-sectionalMedian 48 months since diagnosis4238 medianOffEuroQolMultiD4Norum J \[[@CR52]\]1996CohortCross-sectionalMedian 48 months since diagnosis4238 medianOffEORTC QLQ-C30MultiD3Abrahamsen AF \[[@CR29]\]1998CohortCross-sectionalMean 12 years since diagnosis45944 medianOffStudy-specific questionnaireDomain6Kornblith AB \[[@CR24]\]1998Comparator: CohortCross-sectionalMean 5.9 years post treatment27337 medianOffPAIS-SR, BSI, POMS, IESDomain6Greil R \[[@CR13]\]1999CohortCross-sectionalMean 10.5 years since diagnosis12636.9 meanOffEORTC QLQ-C30MultiD6Kaasa S \[[@CR53]\]1999Comparator: CohortCross-sectional3--20 years post treatment45944 meanOffSF-36, FQMultiD, Symptoms5Loge JH \[[@CR54]\]1999CohortCross-sectionalMean 12.2 years since diagnosis45944 meanOffHADS, FQDomain, Symptom6Loge JH \[[@CR55]\]1999CohortCross-sectionalMean 12.2 years since diagnosis45944 meanOffSF-36MultiD6Van Schaik CS \[[@CR56]\]1999CohortCross-sectionalMedian 21.9 years since diagnosis3321.9 medianOffHUI2, HUI3MultiD3Loge JH \[[@CR32]\]2000CohortCross-sectional3--23 years post treatment42119--74 yearsOffFQ, HADS, Study-specific questionnaireDomain. Symptom6Barr RD \[[@CR57]\]2001Comparator: CohortCross-sectionalCompleted treatment at least 2 years prior19N/SOffHUIMultiD2Cameron CL \[[@CR58]\]2001CohortCross-sectionalMedian 7 years since diagnosis27237 meanOffPAIS-SR, Symptom ReportDomain, Symptom4Knobel H \[[@CR35]\]2001CohortCross-sectionalMean 9 years since diagnosis9237 meanOffFQSymptom6Zabora J \[[@CR59]\]2001CohortCross-sectional58 % diagnosed within 90 days from study135N/SBothBSIDomain3Zebrack BJ \[[@CR43]\]2002Comparator: CohortCross-sectionalMean 16.2 years since diagnosis184330.8 meanOffBSIDomain5Ganz PA \[[@CR10]\]2003Comparator: RCTLongitudinalTrial registration (since diagnosis)24431.4 STLI, 33.7 CMT medianBothSF-36, CARES-SF, SDSMultiD, Symptom4Gil-Fernández JJ \[[@CR27]\]2003CohortCross-sectionalMedian 7.6 years since diagnosis4643 meanOffEORTC QLQ-C30, HADSMultiD, Other5Oldervoll LM \[[@CR36]\]2003CohortLongitudinalMean post treatment: 6.6 years fatigued patients; 4.9 years non-fatigued patients5341 fatigue, 40 non-fatigued meanOffSF-36, FQMultiD, Symptom5Rüffer JU \[[@CR33]\]2003Comparator: Case ControlCross-sectionalMedian 5.2 years since diagnosis81831 medianOffEORTC QLQ-C30, MFI, Life Situation QuestionnaireMultiD, Symptom5Wettergren L \[[@CR60]\]2003CohortCross-sectionalMean 14 years since diagnosis12147 meanOffSEIQol-DWMultiD5Adams MJ \[[@CR16]\]2004CohortCross-sectionalMedian 14.3 years since diagnosis4831.9 medianOffSF-36, Study-specific questionnaireMultiD4Wettergren L \[[@CR28]\]2004CohortCross-sectionalMean 13 years since diagnosis12147 medianOffSF-12, SEIQoL-DW, HADSMultiD, Domain6Hjermstad MJ \[[@CR61]\]2005CohortCross-sectionalMedian 16.3 years since diagnosis49646 medianOffFQSymptom6Ng AK \[[@CR34]\]2005Comparator: CohortCross-sectionalMedian 15 years since diagnosis51144 medianOffFACIT-FatigueSymptom6Wettergren L \[[@CR62]\]2005CohortCross-sectionalMedian 14 years since diagnosis121NSOffSF-12, SEIQoL-DWMultiD2Hjermstad MJ \[[@CR63]\]2006CohortCross-sectionalMedian 16.3 years since diagnosis47946 meanOffSF-36, FQMultiD, Symptom5Mols F \[[@CR21]\]2006CohortCross-sectional5--15 years since diagnosis132NSOffSF-36, QoL-CSMultiD6Absolom K \[[@CR64]\]2007CohortCross-sectional15.7 years mean since diagnosis5039.7 meanOffSF-12, HADSMultiD, Domain5Aksnes LH \[[@CR65]\]2007Comparator: CohortCross-sectionalMean since diagnosis: 14 years for males, 11 years for females8935 meanOffSF-36, HADS, FQMultiD, Domain, Symptom4Oldervoll LM \[[@CR66]\]2007CohortCross-sectionalMean 17 years since diagnosis47646 meanOffFQSymptom5Goodman KA \[[@CR19]\]2008CohortCross-sectionalMedian 12 years post treatment6043 medianOffEORTC QLQ-C30MultiD6Mulrooney DA \[[@CR67]\]2008Comparator: CohortCross-sectionalAt least 15 years since diagnosis995NSOffFACIT-Fatigue, Pittsburgh Slee Quality Index, Epworth Sleepiness ScaleSymptoms4Shimoda S \[[@CR68]\]2008CohortCross-sectionalMean 16.5 years since diagnosis15NSOffHUI3MultiD2Kiserud CE \[[@CR14]\]2009CohortCross-sectionalMean 15.2 follow up years13845.7 meanOffBSFI, Fatigue questionnaire, HADS, SF-36MultiD, Symptom, Domain6Heutte N \[[@CR11]\]2009Comparator: RCTLongitudinalMean 7.5 years since diagnosis93531 medianOffEORTC QLQ-C30, MFI, Sexual Function ScaleMultiD, Symptoms6Brandt J \[[@CR69]\]2010CohortCross-sectionalMedian since diagnosis: HDCT 11 years, conventional chemotherapy 3.5 years9846 HDCT, 41 conventional medianOffEORTC QLQ-C30, EQ-5DMultiD6Klaassen RJ \[[@CR40]\]2010CohortLongitudinal2 weeks after first course of chemotherapy4914.7 meanBothPedsQL, HUI2, HUI3, EuroQol, Lanksy Play-Performance ScoreMultiD, Other4Klaassen RJ \[[@CR41]\]2010Comparator: CohortLongitudinal2 weeks after first course of chemotherapy4914.7 meanBothPedsQL, HUI2, HUI3, EuroQol, Lanksy Play-Performance ScoreMultiD, Other2Miltényi Z \[[@CR17]\]2010CohortCross-sectionalMean 9.8 years since diagnosis16843.11 medianOffEORTC QLQ-C30MultiD6Baptista RLR \[[@CR70]\]2012CohortCross-sectionalMedian 7 years since diagnosis20029 medianOffMFISymptom4Khimani N \[[@CR18]\]2013CohortLongitudinalMedian 24 years since diagnosis27352 medianOffSF-36, FACIT-FatigueMultiD, Symptom5Minn AY \[[@CR20]\]2012CohortCross-sectionalMedian 10.2 years post treatment7126 medianOffEORTC QLQ-C30MultiD5Behringer K \[[@CR12]\]2013Comparator: RCTLongitudinalAt diagnosis320836.4 meanBothEORTC QLQ-C30, MFI, Sexual Health ScaleMultiD, Symptoms6Greaves P \[[@CR39]\]2014Comparator: CohortCross-sectionalMean 20.3 years since diagnosis28053.1 meanOffFACT-BMT, IOC, Study-specific questionnaireMultiD, Other5Hamre H \[[@CR44]\]2013Comparator: CohortCross-sectionalMedian 21.5 years since diagnosis6835 medianOffFQSymptom5Kim S \[[@CR71]\]2014CohortCross-sectionalMean 6.7 years since diagnosis5843.3 meanOffEORTC QLQ-C30, HADSMultiD, Domain6Roper K \[[@CR72]\]2013CohortLongitudinalAt completion of planned therapy4030.9 meanOffSF-12, HADS, SDS, IOCMultiD, Domain, Other4Soares A \[[@CR45]\]2013CohortCross-sectionalMedian 7 years since diagnosis20029 medianOffSF-12, QOL-CS, MOS-SSS, MFIMultiD, Symptom4Vissers PAJ \[[@CR15]\]2013CohortCross-sectionalMean 5 years since diagnosis15047 meanOffEORTC QLQ-C30MultiD6Calaminus G \[[@CR46]\]2014CohortCross-sectionalMean 15.3 years since diagnosis72528.44 meanOffEORTC QLQ-C30MultiD6Daniels LA \[[@CR31]\]2014CohortCross-sectionalMean 4.6 years since diagnosis18046 meanOffEORTC QLQ-C30, Fatigue Assessment Scale, Study-specific questionnaireMultiD, Symtom, Domain6Daniels LA \[[@CR73]\]2014CohortLongitudinalMean 21 years since diagnosis4347 meanOffEORTC QLQ-C30, Fatigue Assessment Scale, HADSMultiD, Domain, Symptom4Oerlemans S \[[@CR25]\]2014Comparator: Case ControlLongitudinalMean 4.7 years since diagnosis18046.1 meanOffEORTC QLQ-C30, HADSMultiD, Domain6Vermaete N \[[@CR47]\]2014Comparator: CohortLongitudinalBefore the start of chemotherapy1247 meanBothEORTC QLQ-C30, Distress BarometerMultiD, Domain5Kiserud CE \[[@CR74]\]2015CohortCross-sectionalMedian 16 years since diagnosis13146 medianOffFatigue questionnaire, HADS, SF36,Symptom, MultiD5Husson O \[[@CR42]\]2015Comparator: CohortCross-sectionalMean 5.3 years since diagnosis15046.6 meanOffFatigue assessment scaleSymptom4*Abbreviations*: *Tx* treatment, *MultiD* multidimensional, *HL* Hodgkin's Lymphoma, *RCT* randomized controlled trial, *EORTC QLQ-C30* European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, *SF-36/SF-12* Short Form, *HUI* Health Utilities Index, *QOL-CS* Quality of Life-Cancer Survivors, *CES-D* Center for Epidemiologic Studies Depression Scale, *GSSI* Global Sexual Satisfaction Index, *IES* Impact of Event Scale, *VAS* Visual Analogue Scale, *CARES-SF* Cancer Rehabilitation Evaluation System-Short Form, *SDS* Symptom Distress Scale, *SEIQol-DW* Schedule for the Evaluation of the Individual Quality of Life-Direct Weighting, *PedsQL* Pediatric Quality of Life Inventory, *MOS-SSS* Medical Outcomes Study-Social Support Survey, *FACT-BMT* Functional Assessment of Cancer Therapy---Bone Marrow Transplant, *FQ* Fatigue Questionnaire, *MFI* Multi-Dimensional Fatigue Inventory, *FACIT-Fatigue* Functional Assessment of Chronic Illness Therapy-Fatigue, *HADS* Hospital Anxiety and Depression Scale, *BSI* Brief Symptom Inventory, *POMS* Profile of Mood States, *PAIS* Psychosocial Adjustment to Illness Scale, *HDCT* high dose chemotherapy, *STLI* subtotal lymphoid irradiation, *CMT* combined modality treatment, *NS* not stated

Patient characteristics {#Sec8}
-----------------------

Age was reported in 54 studies (83 %). Thirty-three studies reported a mean age of 40 years (SD = 8.5) and 21 studies reported median age of 38 years (range 22--52). In 41 (63 %) studies that reported time since diagnosis, the mean was 11.8 years (*n* = 25) and the median was 12.4 years (*n* = 16). Twelve (19 %) studies reported time post treatment, with a mean of 4.8 years (SD = 1.73) (*n* = 4) and a median of 10.2 years (*n* = 3). Five studies reported only a range of years post treatment (1--23 years).

Quality of life measures {#Sec9}
------------------------

Studies varied by aspect of HRQL examined as well as by specific instrument used. Table [3](#Tab3){ref-type="table"} summarizes the various aspects of HRQL by study design (longitudinal vs. cross-sectional). The most commonly used multi-dimensional instruments were the EORTC QLQ-C30 (*n* = 18), the SF-12 or SF-36 (SF-36 Family) (*n* = 18) and Health Utilities Index (HUI) 2, 3 (*n* = 8). Strikingly, all 12 longitudinal studies included a multidimensional scale whereas only 62 % (*n* = 33) of the cross-sectional studies did so. Among cross-sectional studies, the most commonly used measures were the HADS (*n* = 8), Fatigue Questionnaire (*n* = 7), and the EORTC QLQ-C30 (*n* = 7).Table 3Measure type by study design (*N* = 65)HRQL measures, *n* (%)^a^LongitudinalCross-sectional*n* = 12 (18)*n* = 53 (82)Multidimensional12 (100)33 (62)Domain Psychosocial4 (33)20 (38) Sexual functioning2 (17)5 (9) Physical1 (8)0 (0)Symptom Fatigue4 (33)18 (34) Pain0 (0)1 (2) Other2 (4)4 (8)^a^Percentages do not sum to 100 because multiple measures can be used in the same study, *HRQL* health-related quality of life

Multi-dimensional HRQL scores varied by treatment type \[[@CR10], [@CR13], [@CR14]\], age and sex \[[@CR11]\], comorbidities \[[@CR15]\] or late effects \[[@CR16]--[@CR18]\]. Both Khimani and Adams found significantly lower quality of life among HD survivors who experienced cardiopulmonary late effects \[[@CR16], [@CR18]\]. Goodman and Minn found that HD patients undergoing autologous stem cell transplant reported no difference in global HRQL versus the general population, however these patients did experience a decrease in overall cognitive and social health \[[@CR19], [@CR20]\]. Finally, Ganz found that HRQL can improve over the trajectory of treatment into survivorship \[[@CR10]\] and Mols supported this finding that HRQL continues to improve through long-term survivorship \[[@CR21]\].

Among the single domains explored, psychosocial was the most frequently identified with the psychosocial assessments more common in cross-sectional (38 %) compared to longitudinal (33 %) studies. The most frequently used psychosocial instruments included the Hospital Anxiety and Depression Scale (HADS) (*n* = 13), the Brief Symptom Inventory Scale (BSI) (*n* = 6), the Profile of Mood States (POMS) (*n* = 5) and the Psychosocial Adjustment to Illness Scale (PAIS) (*n* = 5). As studies utilized a variety of scales and measures, the results within this domain were inconsistent and the presence of psychosocial distress varied among reports. Early studies indicated that HL survivors experienced increased psychological distress \[[@CR22]--[@CR24]\], which was later supported by Oerlemans \[[@CR25]\]; however, several others studies found no difference in the psychosocial distress of HL survivors when compared to healthy controls \[[@CR26]--[@CR28]\].

The second most commonly assessed domain was sexual health (*n* = 7). When assessing sexual health, researchers used four validated sexual health instruments including the Sexual Health Scale, the Global Sexual Satisfaction Index, the Brief Sexual Function Inventory, and the Sexual Function Scale. Four of the studies indicated that HL survivors report increased SX problems \[[@CR14], [@CR22], [@CR29], [@CR30]\]. These SX problems can improve over time \[[@CR11]\], but may be more long lasting in higher-stage patients \[[@CR12]\].

Several of studies used symptom-specific questionnaires (*n* = 29). Of these symptom assessments, the 76 % majority focused on fatigue (*n* = 22). Other symptom assessments included nausea (*n* = 3), energy level (*n* = 1), pain (*n* = 1) and symptom distress (*n* = 1). The three most commonly used fatigue instruments included the Fatigue Questionnaire (FQ) (*n* = 12), the MFI (*n* = 5), and the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) (*n* = 3). Results in this domain were more homogenous with multiple studies indicating that HL survivors are at increased risk for fatigue when compared to healthy controls \[[@CR10], [@CR31]--[@CR34]\]. Studies within this domain found correlations between fatigue and depression (\[[@CR15], [@CR32]\] and fatigue and cardiopulmonary late effects \[[@CR18], [@CR35]\]. One longitudinal study with a small sample size showed that an exercise intervention can improve fatigue in HL survivors \[[@CR36]\].

In our review, 63 (97 %) studies used at least one validated instrument. Two exceptions reported by Abrahamsen \[[@CR29]\] and Chao \[[@CR37]\], used only non-validated, study-specific questionnaires. Six other studies incorporated a study specific questionnaire in addition to a validated instrument. Of these, three included broad questions including demographic, medical and psychosocial information \[[@CR26], [@CR38], [@CR39]\], while the other three created assessment tools specific to their study question pertaining to cardiac health \[[@CR16]\], patient screening \[[@CR31]\], and psychiatric disorders \[[@CR32]\].

Quality assessment {#Sec10}
------------------

Our quality assessment was based upon six criteria (Table [4](#Tab4){ref-type="table"}). Nearly 86 % (*n* = 56) of all of the studies included more than two demographic variables and clinical characteristics. The majority (*n* = 53, 82 %) also reported quality of life scores---specifically including a mean score and standard deviation (SD) in table or text form. Of the 11 studies that did not fulfill this criteria, five presented the data graphically \[[@CR10], [@CR12], [@CR40]--[@CR42]\]; three used the data to dichotomize groups (e.g., fatigued vs. non-fatigued population) \[[@CR36], [@CR43], [@CR44]\]; two provided means scores but no standard deviation \[[@CR41], [@CR45]\]; one provided the percentages of negative impact of sexual function used to compare between groups \[[@CR39]\], and one reported the percentage of sexual problems \[[@CR29]\]. Most (*n* = 53, 82 %) of the studies compared results of individuals with HL with other groups such as siblings, general population or other individuals with cancer and 78 % of the studies included a sample size greater than 50. For the final criteria, 69 % of the studies included an analysis of HL HRQL scores stratified by HL specific characteristics.Table 4Quality Assessment of Hodgkin Lymphoma Specific StudiesQuality indicatorLongitudinal (*n* = 12)Cross-sectional (*n* = 53)Total (*N* = 65)Sample \>50 (HL Specific)6 (42)45 (85)51 (78)Description of \>=2 Demos (HL Specific)10 (83)48 (91)58 (89)Description of \>=2 Clinical Variables (HL Specific)11 (92)45 (85)56 (86)HL Specific HRQL Scores (from validated measure)8 (67)45 (85)53 (82)Analysis of HL HRQL Scores × HL Characteristics8 (67)37 (70)45 (69)HL Results are compared between groups?9 (75)44 (83)53 (82)*HL* Hodgkin's Lymphoma*, HRQL* health-related quality of life

Key articles {#Sec11}
------------

The following section highlights specific studies with a focus on their methodological rigor. The 2013 prospective study by Behringer et al. \[[@CR12]\] was embedded within German Hodgkin Study Group HD10-HD12 trials. This study included the largest sample within our review, 3208 patients, and followed these patients from diagnosis through up to 27 months of follow-up care. Patients were randomized to varying protocols of HL chemotherapy and radiation, according to each of the three clinical trials. This study ultimately focused on the sexual functioning (SX) domain; however it also collected multi-dimensional HRQL data. Studies instruments included the European Organization for Research and the Treatment of Cancer (EORTC-QLQ-C30), Multi-dimensional Fatigue Inventory (MFI) and a Sexual Functioning Scale. Researchers found that while SX was reduced at baseline, it improved after therapy and eventually normalized in individuals with early stage disease. Within the HD11 trial, which was a randomized comparison of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) versus bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP), a small but significant difference of SX symptoms was detected in favor of ABVD. Long-term SX was related more to baseline SX and patient characteristics than to the intensity of treatment. Of note, older age, advanced stage disease, and female gender had an overall negative influence on SX.

From a quality perspective, the researchers used validated, multi-dimensional assessment tools; however they did not report specific means scores or the standard deviation. Instead, they used the HRQL data as independent variables to predict/explain sexual function and reported it in graph format. This absence of summary scores and variance precludes performing meta-analysis from these published data.

In 2003 Ganz et al. \[[@CR10]\] conducted the only RCT of HRQL in HL in the US. This study was embedded in a RCT in cooperative Southwest Oncology Group 9133 trial. It included 247 patients in a prospective, longitudinal design, evaluating multidimensional HRQL at baseline, 6 months, 1 and 2 years. Researchers found a statistical difference in HRQL between the two treatments subtotal lymphoid irradiation with combined modality treatment (CMT). Specifically, the CMT arm experienced greater symptom distress, fatigue and poorer overall HRQL; however, by years 1 to 2, patients with in the two groups did not differ in outcomes. The authors also reported that both groups experienced significantly increased fatigue at 6 months from baseline (when compared to healthy populations) and this persisted even 1--2 years after treatment.

This study used a high quality methodology with a prospective, longitudinal, RCT design, a large sample size, and validated multi-dimensional assessment tools; however, like Behringer \[[@CR12]\], they did not report specific means scores or the standard deviation, but instead presented trends over time graphically.

Heutte et al. \[[@CR11]\] conducted a prospective, longitudinal study assessing HRQL among patients treated on the H8 study in Europe. This study included 935 patients, who were assessed at the end of therapy and serially up 10 years following treatment using the EORTC-QLQ-C30, MFI, and sexual function scale. Their results indicated that the emotional functioning scores were more affected than the physical functioning scores, and that women reported lower HRQL and increased symptom distress than men. All of the HRQL domains they evaluated showed improvement within 18 months of treatment completion with the exception of cognitive function and motivation. The authors suggest that neither of these domains were affected by the HL or treatment. Finally, they found that high levels of fatigue at end of treatment predicted persistent fatigue into long-terma follow-up. They did not find any differences between the treatment groups. Methodologically, this study included a large xsample size, randomization between treatment groups and used validated, multi-dimensional assessment tools. Methodologic concerns included the lack of baseline data (prior to initiation of treatment) and no data obtained during treatment.

Calaminus et al. \[[@CR46]\] conducted a cross-sectional study assessing HRQL in pediatric survivors, who were previously treated for HL in German-Austrian RCT studies from 1978 to 2002. This study enrolled 725 participants, who were assessed using the EORTC QLQ-C30. Results were compared to a similarly matched general population sample. Several of the results of this study are similar to Heutte's: survivors experienced worse emotional and social functioning compared to normal population; females experience lower over-all functioning and higher symptom burden than men; survivors experienced greater symptoms of fatigue and sleep problems. Again, there was no relationship between the treatment types. Methodologically, this study included a large sample size, validated instruments and comparisons between groups. Although it did not follow patients over time, the study does illustrate how a well-designed cross sectional study can support longitudinal findings.

Klaassen et al. \[[@CR40]\] examined the ability to detect change over time in four different HRQL measures. In their prospective study of 48 patients, patients were assessed at four points in time: 2 weeks after first course of chemotherapy, during the second course of chemotherapy, during their week of radiation and 1 year after diagnosis. All of the HRQL measures demonstrated significant change from Time 1 to Time 4. In a second study, Klaassen \[[@CR41]\] also examined proxy reporting by parents and nurses of children with HL to determine if correlation with children's report. In this study, the authors found that over the course of treatment there was statistical significant agreement among the child, parent and nurse, as measured by the Spearman rank-order correlation coefficient. Methodologically, this study used validated tools and compared trends over time; however, concerns include its small sample size, no baseline data, no randomization according to the treatment arm or disease stage and the absence of means scores with standard deviations.

Vermaete et al. \[[@CR47]\] conducted a longitudinal study to assess fatigue, physical activity and physical fitness in individuals with lymphoma before, during and after treatment. This study included 29 patients with either HL (*n* = 12) or Non-Hodgkin Lymphoma (*n* = 17). Over course of treatment, researchers detected a decline in hemoglobin, physical force and oxygen uptake, and patients reported significantly increased fatigue. This study looks deeper into the complex relationship between fatigue, physical inactivity and deconditioning and support further work in developing exercise interventions. Methodologically, this study used validated tools, obtained baseline prior to the start of treatment and provided mean scores with standard deviation; however, it enrolled a small sample size and did not randomize according to the treatment arm or disease stage.

Discussion {#Sec12}
==========

In our review the majority of studies employed cross-sectional versus longitudinal design and of these cross-sectional studies, 98 % enrolled participants off treatment. These cross sectional studies capture patients within a wide range of time periods after diagnosis, on average, 10 years after treatment. While cross sectional studies provide a "snap shot in time," analyzing a group one decade after treatment introduces the risk of many confounding variables, which makes it difficult to build a cohesive narrative around the impact of HL and its treatment on HRQL. In terms of assessing HRQL, all longitudinal studies used a multi-dimensional measure compared to 62 % of cross-sectional studies, which focused more on specific domains and symptoms, especially fatigue.

The objective of this review was to systematically identify published studies reporting HRQL in individuals with HL, and to examine the quality of these studies. Our analysis points to several positive trends in the literature. First, it is clear that that over time there has been a growing interest in this topic, as the number of studies that examine HRQL has increased. As noted, half of the studies identified in this review were published after 2005 (*n* = 34). The second positive trend is movement toward more longitudinal studies with nine of the 12 published since 2009. In regard to patient reported outcomes in HRQL, the majority of studies used at least one multidimensional instrument (*n* = 45) and 97 % of studies included at least one validated instrument.

We also noted several concerns with quality of the current literature. The most rigorous methodology employs a longitudinal design with comparison between groups and changes within subjects. Our review identified only 12 longitudinal studies with ten unique data sets. Only five out of the 12 studies followed patients from diagnosis through to post-treatment and of these only two included at least 50 patients. Reporting HRQL data also varied across the longitudinal studies with four reporting results graphically without mean summary scores and measures of variability \[[@CR10], [@CR12], [@CR40], [@CR41]\], which prevents further meta-analysis.

Behringer and colleagues \[[@CR12]\] illustrate the complex and informative data that can be derived from prospective, longitudinal designs. It provides clinician's with a deeper understanding of the trajectory of SX from diagnosis through treatment; additionally, it describes how SX differs across treatment groups and identifies those specific populations, who are most vulnerable. This information can assist clinicians in providing anticipatory guidance and targeted-interventions to the most vulnerable populations.

Results from Ganz and colleagues \[[@CR10]\] inform clinicians that symptom burden can vary between treatment groups; however fatigue can persist over time. Clinicians could use this information to guide CMT patients to be more realistic with short-term goals immediately after treatment and to initiate more aggressive symptom management interventions. Second, in regard to fatigue, clinicians could use this information to prepare their patients for fatigue, continue to assess for fatigue during follow-up care and to support further research and interventions in fatigue prevention and management.

Relevance to research and clinical practice {#Sec13}
-------------------------------------------

This systematic review reveals the paucity of information on the HRQL impact of initial diagnosis and treatment on HL patients. The majority of published studies are cross-sectional in design and relatively small in size; only 36 studies have sample sizes \>100 (Table [2](#Tab2){ref-type="table"}). This limits the application of study findings due to concerns about generalizability and reproducibility. That said, the few longitudinal studies commencing prior to the initiation of treatment, detailed on page 11, provide such information about HRQL trajectory and how it changes over time and by treatment. These findings offer compelling evidence for the need to replicate these measures in future trials.

This study has several strengths. First, we followed PRISMA guidelines to systematically search the literature to capture the complete and relevant published literature. Second, the quality assessment methods provided a standardized measure by which all articles were evaluated. Last, we highlighted the subset of articles which exemplify best practices to examine HRQL in HL patients, with the goal of building upon these methods and findings in future research.

Limitations {#Sec14}
-----------

There are limitations to this study. First, because of the lack of RCTs on this topic, we included observational studies, which are more open to bias. Second, we did not conduct an assessment of publication bias as our aim was to analyze the quality rather than to meta-analyze the findings. Last, most HRQL assessments were completed post-treatment so the longitudinal trajectory of HRQL was not captured. More large-cohort, prospective studies are needed to address this limitation.

Conclusions {#Sec15}
===========

HL is a highly curable disease with standardized treatment paradigms over the last two decades. Although the treatment is well established, a knowledge gap still exists in understanding how this diagnosis and its treatment affect the individual's HRQL from diagnosis though long-term survivorship. Further, with the exception of an ongoing pediatric cooperative group trial, we found no prospective pediatric studies reporting on HRQL in HL from diagnosis to survivorship. Even in adult studies, we identified a substantial void of HRQL data during the active treatment phase. Finally, we identified no industry-funded studies, although this may change with the emergence of novel therapeutics.

With the growing interest and acknowledgement of the importance of HRQL, we recommend that future research studies employ greater methodological rigor by including prospective, longitudinal randomized designs across both treatment and time. Behringer \[[@CR12]\], Heutte et al. \[[@CR11]\] and Ganz \[[@CR10]\], provide a "gold standard" of research studies that not only examine longitudinal effects within subject changes, but also provide comparisons between different treatment regimens. The information generated by these longitudinal studies helps clinicians target vulnerable populations and provide anticipatory guidance to patients. Such studies will generate further data that clinicians can use to address "real life" HRQL problems that patients face on a day-to-day basis. Further, while research supports that HRQL improves after treatment, continued deficits in some patients within the domains of fatigue, sexual and psychosocial health warrants further study with targeted interventions to mitigate the risk of poorer HRQL. Finally, as the focus on HRQL continues to grow in importance, researchers should consider partnering with industry to examine oncologic treatments within the context of how they will impact the patient's HRQL.
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